Unicycive raises up to $130M in private placement led by Vivo Capital for Renazorb launch

Unicycive Therapeutics, Inc.

$30M upfront from Series A-1 Convertible Preferred Stock; up to $100M additional via milestone-linked warrants.
Tranche A warrants ($25M) exercisable upon FDA approval of Renazorb; Tranche B ($25M) upon TDAPA approval; Tranche C ($50M) after four quarters of commercial sales.
Gaurav Aggarwal, MD (Vivo Capital) appointed to Board of Directors effective at closing.
Company to adopt dividend policy paying at least 75% of annual net cash flow from operations to all stockholders post-approval and commercial sales.
Proceeds to support NDA submission for Renazorb (hyperphosphatemia) and potential U.S. commercial launch.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gaurav Aggarwal

Director

UNCY · Unicycive Therapeutics, Inc.

Filed: March 6, 2023, 6:59 PM ET

effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gaurav Aggarwal was appointed as Director at Unicycive Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Unicycive Therapeutics, Inc.: Gaurav Aggarwal, MD was appointed to the Board of Directors effective upon closing of the offering, with standard non-employee director compensation and indemnification (effective 2023-03-06).

Effective: 2023-03-06

Exact text from the filing

Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Unicycive Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at $30 million (effective 2023-03-03).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $30 million
Effective: 2023-03-03

Exact text from the filing

On March 3, 2023, Unicycive Therapeutics , Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell, in a private placement (the " Offering "), 30,190 shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share (the " Series A-1 Preferred Stock "), for an aggregate offering price of $30 million.

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-017841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.